Pre-analysis cell sorting for the MayoComplete Plasma Cell Myeloma panel
Only orderable as a reflex. For more information see NGPCM / MayoComplete Plasma Cell Myeloma, Next-Generation Sequencing, Varies.
Flow Cytometric Cell Selection
Bone Marrow
Only orderable as a reflex. For more information see NGPCM / MayoComplete Plasma Cell Myeloma, Next-Generation Sequencing, Varies.
2 mL
Gross hemolysis | Reject |
Gross lipemia | OK |
Bone marrow biopsies Slides Paraffin shavings Frozen tissues Paraffin-embedded tissues Paraffin-embedded bone marrow aspirates Extracted DNA Bone marrow aspirate samples with <15% plasma cells by cytologic differential count | Reject |
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Bone Marrow | Ambient | 4 days |
Pre-analysis cell sorting for the MayoComplete Plasma Cell Myeloma panel
Testing allows for further risk categorization of multiple myeloma (MM) through identifying additional abnormalities of prognostic and, potentially, therapeutic value. Application of targeted next-generation sequencing-based analysis is a useful adjunct to the standard evaluation of MM patients at diagnosis and relapse.
Only orderable as a reflex. For more information see NGPCM / MayoComplete Plasma Cell Myeloma, Next-Generation Sequencing, Varies.
Not applicable
Correlation with clinical, histopathologic, and additional laboratory findings is required for final interpretation of these results. The final interpretation of results for clinical management of the patient is the responsibility of the managing physician.
No significant cautionary statements
1. Walker BA, Boyle EM, Wardell CP, et al: Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma. J Clin Oncol. 2015 Nov;33(33):3911-3920
2. Morgan GJ, Walker BA, Davies FE: The genetic architecture of multiple myeloma. Nat RevCancer. 2012 Apr;12(5):335-348
3. Kortuem KM, Braggio E, Bruins L, et al: Panel sequencing for clinically oriented variant screening and copy number detection in 142 untreated multiple myeloma patients. Blood Cancer J. 2016 Feb;6(2):e397
4. Kortuem KM, Mai EK, Hanafiah NH, et al: Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes. Blood. 2016 Sept;128(9):1226-1233
Selection of plasma cells using fluorescence-activated cell sorting is the most direct and robust method of obtaining relatively pure plasma cell populations for molecular assessment. This, in turn, augments the ability to identify key mutations and subclonal variants of possible clinical value without dilution effects from non-tumor cell DNA.(Instruction manual: Cell Sorter Operator's Guide. Sony Corporation; LE-SH800, 2015)
Monday through Saturday
This test was developed, and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.
88184-Flow Cytometry; first cell surface, cytoplasmic or nuclear marker
88185 x 5-Flow Cytometry, additional cell surface, cytoplasmic or nuclear marker (each)
Test Id | Test Order Name | Order LOINC Value |
---|---|---|
CSPMM | NGPCM Pre-Analysis Cell Sorting, BM | No LOINC Needed |
Result Id | Test Result Name |
Result LOINC Value
Applies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.
|
---|---|---|
618627 | NGPCM Pre-Analysis Cell Sort | No LOINC Needed |
618630 | Final Diagnosis | 22637-3 |
Change Type | Effective Date |
---|---|
New Test | 2022-12-13 |